Skip to main
IMVT

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant is a promising company with strong revenue potential due to its focused approach on developing IMVT-1402, a potential inhibitor of the FcRn receptor. Risks to its price target achievement include regulatory and clinical hurdles, the impact of COVID-19 on clinical development, and potential competition in the market. With the failure of its other drug in Phase 3 trials, the company is now fully dedicated to developing IMVT-1402 and has upcoming topline data from potentially registrational trials expected in 2027.

Bears say

Immunovant is in a strong position with their lead candidate IMVT-1402 showing robust response rates in highly refractory RA patients, with efficacy maintained in JAK-refractory patients. However, there are concerns regarding regulatory and clinical risks due to the potential cholesterol safety signal and the impact of COVID-19 on clinical development. Additionally, as a first-time product launch in a competitive market, there are financial risks with projected revenue not expected until 2027.

Immunovant Inc (IMVT) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 9 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.